Targeted next-generation sequencing of 565 neuro-oncology patients at UCLA: A single-institution experience.

ABSTRACT:

Background

Targeted next-generation sequencing (NGS) is frequently obtained at the University of California, Los Angeles (UCLA) for clinical characterization of CNS tumors. In this study, we describe the diagnostic reliability of the Foundation Medicine (FM) targeted NGS platform and its ability to explore and identify tumor characteristics of prognostic significance in gliomas.

Methods

Neuro-oncology patients seen at UCLA who have received FM testing between August 2012 and March 2019 were included in this study, and all mutations from FM test reports were recorded. Initial tumor diagnoses and diagnostic markers found via standard clinical methods were obtained from pathology reports. With overall and progression-free survival data, elastic net regularized Cox regression an

SUBMITTER: Ji MS 

PROVIDER: S-EPMC7034640 | biostudies-literature | 2020 Jan-Dec

REPOSITORIES: biostudies-literature